RT Journal Article
SR Electronic
T1 The Expression Level of <em>PD-L1</em> (<em>CD274</em>) mRNA in Peripheral Blood Is a Potential Biomarker for Predicting Recurrence in Breast Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3733
OP 3742
DO 10.21873/anticanres.14362
VO 40
IS 7
A1 TAKAAKI MASUDA
A1 MIWA NODA
A1 AKIHIRO KITAGAWA
A1 QINGJIANG HU
A1 ATSUSHI FUJII
A1 SHUHEI ITO
A1 KEISUKE KOSAI
A1 YUKI ANDO
A1 YOSHIHIRO MATSUMOTO
A1 HAJIME OHTSU
A1 HIROKI UCHIDA
A1 SHINJI OHNO
A1 KOSHI MIMORI
YR 2020
UL http://ar.iiarjournals.org/content/40/7/3733.abstract
AB Background/Aim: Programmed death-ligand 1 (PD-L1/CD274) elicits T-cell anergy, leading to immune suppression. We aimed to determine the prognostic relevance of PD-L1 expression in the blood of breast cancer (BC) patients. Materials and Methods: We measured PD-L1 mRNA expression in blood and tumor tissues of BC patients using RT-qPCR and a dataset from The Cancer Genome Atlas, and performed a survival analysis of PD-L1 expression in the blood of 330 BC patients. Flow cytometric analysis was performed using blood cells. Results: No statistical difference in PD-L1 expression was seen between normal controls and BC in blood or tissues. There was a significant positive correlation between the PD-L1 expression levels in blood and tissues. Decreased PD-L1 expression in blood or tissues was associated with poor recurrence-free survival. PD-L1 is mainly expressed in polymorphonuclear leukocytes. Conclusion: Low expression of PD-L1 in the blood could serve as a biomarker of poor prognosis in BC patients.